Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Diversify into RBI-regulated P2P lending platforms and earn up to 11.5% p.a.
Invest in curated
corporate, gold, and govt. bonds
Earn income
while helping India move to clean energy
Connect with investors, share insights, and grow together.
Master the world of Alternative Investments with our in-depth courses
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning.
Read about our journey and get to know the leadership team at Vested
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. more
Time Frame | AGEN | S&P500 |
---|---|---|
1-Week Return | 2.59% | 2.05% |
1-Month Return | 29.82% | 1.43% |
3-Month Return | -19.05% | 5.3% |
6-Month Return | -41.76% | 12.75% |
1-Year Return | -69.56% | 25.72% |
3-Year Return | -93.24% | 38.66% |
5-Year Return | -95.19% | 85.64% |
10-Year Return | -96.54% | 197.6% |
Time Frame | AGEN | S&P500 |
---|---|---|
1-Week Return | 279.36% | 188.09% |
1-Month Return | 2,293.26% | 18.86% |
3-Month Return | -57.56% | 23.30% |
6-Month Return | -66.59% | 27.55% |
1-Year Return | -69.56% | 25.72% |
3-Year Return | -59.26% | 11.51% |
5-Year Return | -45.50% | 13.17% |
10-Year Return | -28.57% | 11.52% |
Sector | Weight |
---|---|
Health Care | 100.00% |
Agenus Inc (AGEN) share price today is $3.57.
Yes, Indians can buy shares of Agenus Inc (AGEN) on Vested. To buy AGEN from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Agenus Inc (AGEN) on Vested. You can start investing in Agenus Inc (AGEN) with a minimum investment of $1.
The 52-week high price of Agenus Inc (AGEN) is $19.69. The 52-week low price of Agenus Inc (AGEN) is $2.5.
The stock symbol (or ticker) of Agenus Inc is AGEN.
Yes, you can setup SIP in Agenus Inc shares. Follow the below steps to create the SIP:
Here is the historical performance of AGEN on the Vested app.
You can also access the top holdings, the expense ratio, and the sector breakdown for Agenus Inc on Vested.
The expense ratio of Agenus Inc (AGEN) is .